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Idiopathic pulmonary fibrosis (IPF) is considered to be the most 
common form of pulmonary fibrosis.[1] It is progressive and 
irreversible, with a reported median survival of ~3 years.[1,2] The 
pathological correlate is usual interstitial pneumonia (UIP). The 
presentation tends to be insidious, with imaging features that are 
irreversible and progressive.[2,3] Antifibrotic agents are currently 
the only medication shown to slow lung function decline; however, 
they do not reverse the disease process.[4,5] To date, there have been 
no case reports describing reversal of UIP. We present a case where 
both the imaging and histology were compatible with definite UIP, 
yet it reversed with immunosuppressive therapy without the use of 
antifibrotic agents.
Case report
A 59-year-old man presented with a 2-week history of worsening 
dyspnoea, dry cough and associated fever. He was a non-smoker, 
healthy prior to this presentation, and maintained a very active 
lifestyle, including participating in an adventure cave run 5 months 
before the onset of his current symptoms. Before referral, he was 
treated unsuccessfully with antibiotics. 
Clinical examination revealed a cyanotic patient with a respiratory 
rate of 24 breaths per minute and an oxygen saturation of 66% on 
room air. He was afebrile and had a normal blood pressure and pulse 
rate. He had bibasal crackles, had no finger clubbing, was not wasted 
and had no generalised lymphadenopathy. The rest of the physical 
examination was unremarkable, with no features of collagen vascular 
diseases. His initial partial pressure of arterial oxygen (PaO2) was 
7 kPa, with a partial pressure of carbon dioxide in arterial blood 
(PaCO2) of 3.4 kPa on room air, necessitating non-invasive positive 
pressure ventilation.
His initial chest radiograph demonstrated bilateral diffuse reticular 
shadowing (Fig. 1A). He tested negative for HIV and had a C-reactive 
protein of 147 mg/L (normal <10 mg/L). Sputum microscopy and 
culture revealed no bacteria or fungi, and sputum GeneXpert (Cepheid, 
USA) was negative. His urinary antibody test for Legionella pneumonia 
and all serological autoimmune tests were negative. 
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Fig. 1. Imaging. (A) Chest radiograph showing bilateral interstitial infiltrates with areas of confluence in the lower zones. (B) A high-resolution computed 
tomograph (HRCT) of the lungs, demonstrating dominant basal subpleural reticulation, traction bronchiectasis and early honeycomb changes. (C) A repeat 
HRCT revealing a remarkable improvement in reticulation, honeycombing and traction bronchiectasis, with only minimal residual peripheral disease.
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On presentation, he was treated empirically with intravenous 
antibiotics and antifungals, with no clinical response. 
His initial pulmonary function testing was suggestive of a 
restrictive defect, with a ratio of volume of gas exhaled during the 
first second of forced expiration (FEV1) to the maximum volume of 
gas exhaled from the position of maximal inspiration by means of 
maximally forced vital capacity (FVC) of 0.9. His total lung capacity 
(TLC) was 48.8% predicted, and diffusion capacity for carbon 
monoxide (DLCO) was severely impaired at 28.2%. 
A high-resolution computerised tomogram (HRCT) revealed 
peripheral reticulation, extensive subpleural honeycombing, and 
traction bronchiectasis predominating in the lower lobes (Fig. 1B). 
Because of the subacute presentation and lack of obvious 
exposure history we opted to perform an open lung biopsy. 
Histology revealed interstitial expansion with fibroblastic foci and 
architectural distortion with mild to moderate inflammation, as 
well as uninvolved foci with alveolar dilatation (Fig. 2). There was 
no granulomatous inflammation, multinucleated giant cells, foreign 
material or eosinophilic infiltrate. All the bacteriological, viral 
and fungal cultures of the biopsied tissue were negative, and the 
histological diagnosis of definite UIP was made.[2]
The patient was provisionally diagnosed with IPF, given the 
absence of a secondary cause of UIP. However, there was a 
perplexing discordance between the degree of fibrosis and the 
reported duration of symptoms. We elected for an in-hospital 
trial of prednisone 60 mg, which was weaned during his 6-week 
admission because of a good clinical response. Azathioprine 150 mg 
was started on discharge. 
After 3 months, his dyspnoea had completely resolved and he 
had begun cycling. Objectively, his FVC had improved to 83%, his 
TLC to 85% and his DLCO to 81.3%. His lung function essentially 
normalised at 1-year follow-up. A repeat HRCT (Fig. 1C) revealed 
a remarkable improvement in reticulation, honeycombing and 
traction bronchiectasis, with only minimal residual peripheral 
disease remaining. 
All immunosuppressive therapy was discontinued after his 
6-month review, and he remained asymptomatic. To date, he has 
not developed an autoimmune disease, and a repeat autoimmune 
serological screen performed 6 months after discontinuing therapy 
remained negative.
Discussion
In contrast to our patient’s subacute clinical presentation, IPF is 
classically associated with a more insidious onset and chronic 
course.[1] Our patient’s convincing radiological and histopathological 
diagnosis of IPF was discordant with his clinical presentation, 
causing us to consider alternative diagnoses. His history of cave 
running 5 months before, although tantalising for a fungal infection, 
was deemed too long before presentation to be the cause in an 
immunocompetent individual, and was additionally excluded on 
both histology and culture. It is possible that such an exposure could 
initiate a subacute hypersensitivity pneumonitis; however, the lack of 
any confirmatory histology or suggestive radiology made this entirely 
speculative. 
Similarly, an evolving autoimmune disease seemed highly unlikely 
owing to the complete lack of clinical or serological evidence up to 
18 months after presentation. Other secondary causes for the UIP 
pattern were diligently excluded at presentation.
The most remarkable feature of this case was the almost complete 
resolution of what was labelled as fibrosis both on imaging and 
histology. Acute exacerbations of a chronic interstitial lung disease 
can respond to immunosuppression; however, normalisation of 
pulmonary function tests and chronic radiological abnormalities 
would be extremely unusual. Undoubtedly, subacute hypersensitivity 
pneumonitis (HP) can resolve completely with immunosuppression. 
Chronic HP can cause a UIP-type pattern and mimic IPF, but the 
extent of fibrosis in such patients is significant, and residual fibrosis 
and symptoms after treatment are usual. Therefore, both acute and 
chronic HP diagnoses are problematic. 
Despite fulfilling the diagnostic criteria for definite, biopsy-proven 
IPF, idiopathic nonspecific interstitial pneumonia or HP is the 
Fig. 2. Histology (haematoxylin and eosin stained) obtained by means 
of open lung biopsy. (A) Subpleural architectural distortion with fibrosis 
(star) and abnormal airspaces and bronchiolar metaplasia (arrow) (100× 
magni fication). (B) Significant peribronchiolar interstitial expansion 
by chronic inflammation associated with loose fibroblastic tissue (star) 
(100× magnification). (C) Interstitial expansion by chronic inflammation 
(lymphocytes and plasma cells) (star) with occasional fibroblastic foci 
(arrow) (200× magni fication).
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most plausible alternative explanation for our patient’s presentation. 
However, using either of these diagnostic labels is equally flawed. 
This case highlights that a degree of clinical acumen is still 
needed when following the guidelines for chronic lung diseases. An 
appreciation of the deviation of our patient’s presentation from the 
usual natural history of IPF prompted a trial of immunosuppressive 
therapy, which is not currently recommended, and has been 
considered harmful in IPF.[6] The resolution of proven fibrosis 
remains perplexing, but his clinical improvement cannot be debated. 
Teaching points
• Clinical acumen is paramount when following guidelines related to 
diffuse parenchymal lung diseases.
• IPF is a diagnosis of exclusion.
• There are many causes of radiological UIP, e.g. IPF, chronic HP 
and rheumatoid lung disease.
Acknowledgements. We acknowledge the Division of Cardiothoracic 
Surgery, Department of Surgical Sciences, Tygerberg Hospital and 
Stellenbosch University, where the open lung biopsy was performed.
Author contributions. DS, BWA and CFNK wrote the manuscript, which 
was reviewed by all co-authors.
Funding. None.
Conflicts of interest. None.
1. Koegelenberg CFN, Ainslie GM, Dheda K, et al. Recommendations for the management of idiopathic 
pulmonary fibrosis in South Africa: A position statement of the South African Thoracic Society. 
J Thor Dis 2016;8(12):3711-3719. https://doi.org/10.21037/jtd.2016.12.05
2. Raghu G, Collard HR, Egan JJ, Martinez FJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary 
Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824. https://
doi.org/10.1164/rccm.2009-040GL
3. Collins CD, Wells AU, Hansell DM, et al. Observer variation in pattern type and extent of disease 
in fibrosing alveolitis on thin section computed tomography and chest radiography. Clin Radiol 
1994;49(4):236-240. 
4. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients 
with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171(9):1040-1047. https://doi.
org/10.1164/rccm.200404-571OC
5. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 
2010;35(4):821-829. https://doi.org/10.1183/09031936.00005209
6. Raghu G, Anstrom KJ, King TE jun., Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetyl-
cysteine for pulmonary fibrosis. N Engl J Med 2012;366(21):1968-1977. https://doi.org/10.1056/
NEJMoa1113354
Accepted 17 May 2018.
